- Home
- SOTK vs RLMD Comparison
SOTK vs RLMD Comparison
Compare SOTK & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOTK
- RLMD
- Stock Information
- Founded
- SOTK 1975
- RLMD 2004
- Country
- SOTK United States
- RLMD United States
- Employees
- SOTK N/A
- RLMD 17
- Industry
- SOTK Industrial Machinery/Components
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- SOTK Technology
- RLMD Health Care
- Exchange
- SOTK Nasdaq
- RLMD Nasdaq
- Market Cap
- SOTK 52.1M
- RLMD 52.8M
- IPO Year
- SOTK 1987
- RLMD N/A
- Fundamental
- Price
- SOTK $3.91
- RLMD $1.59
- Analyst Decision
- SOTK Hold
- RLMD Buy
- Analyst Count
- SOTK 1
- RLMD 3
- Target Price
- SOTK N/A
- RLMD $5.00
- AVG Volume (30 Days)
- SOTK 28.0K
- RLMD 1.6M
- Earning Date
- SOTK 10-14-2025
- RLMD 11-06-2025
- Dividend Yield
- SOTK N/A
- RLMD N/A
- EPS Growth
- SOTK N/A
- RLMD N/A
- EPS
- SOTK 0.09
- RLMD N/A
- Revenue
- SOTK $20,606,116.00
- RLMD N/A
- Revenue This Year
- SOTK $0.56
- RLMD N/A
- Revenue Next Year
- SOTK $8.95
- RLMD N/A
- P/E Ratio
- SOTK $43.45
- RLMD N/A
- Revenue Growth
- SOTK N/A
- RLMD N/A
- 52 Week Low
- SOTK $3.23
- RLMD $0.24
- 52 Week High
- SOTK $6.05
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- SOTK 64.13
- RLMD 74.57
- Support Level
- SOTK $3.82
- RLMD $1.44
- Resistance Level
- SOTK $4.23
- RLMD $1.72
- Average True Range (ATR)
- SOTK 0.18
- RLMD 0.24
- MACD
- SOTK 0.07
- RLMD 0.05
- Stochastic Oscillator
- SOTK 65.59
- RLMD 86.90
About SOTK Sono-Tek Corporation
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.